share_log

Stifel Maintains Hold on Deciphera Pharmaceuticals, Raises Price Target to $18

Benzinga Real-time News ·  Sep 27, 2022 07:02

Stifel analyst Bradley Canino maintains Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Hold and raises the price target from $11 to $18.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment